Eloxx Pharmaceuticals Inc - Company Profile
Powered by 
All the sales intelligence you need on Eloxx Pharmaceuticals Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Eloxx Pharmaceuticals Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Eloxx Pharmaceuticals Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Eloxx Pharmaceuticals Inc (Eloxx) is a clinical-stage biopharmaceutical company. It develops RNA-modulating drug candidates for the treatment of rare and ultra-rare premature stop codon diseases. The company's lead product candidate, ELX-02, is in Phase III clinical trials for the treatment of cystic fibrosis. Its preclinical candidates include novel ERSG drug candidates for the treatment of autosomal dominant polycystic kidney disease (ADPKD) and Usher syndrome. It focuses on developing protein restoration therapies aimed at addressing genetic diseases. The company's major products include platform technologies such as Turbo ZM and Ribosome Modulating Agents (RMAs), specifically Eukaryotic Ribosomal Selective Glycosides (ERSGs). These technologies are designed to correct nonsense mutations and ribosomal mutations, with applications in rare diseases like Alport Syndrome, Recessive Dystrophic Epidermolysis Bullosa, and Familial Adenomatous Polyposis. Eloxx is headquartered in Arlington, Massachusetts, the US.
Headquarters
United States of America
Address
10 Court Street, Arlington, Massachusetts, 02476
Website
www.eloxxpharma.com
Telephone
1 781 5775300
No of Employees
10
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ELOX (NASD)
EPS
XYZ
Net Income (2024)
XYZ
-90.7%
(2024 vs 2023)
Market Cap*
$73.3M
Net Profit Margin (2023)
XYZ
0.0%
(2024 vs 2023)
* As of and is in US$
Eloxx Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline: | Turbo-ZM |
| ELX-02: Alport Syndrome | |
| ZKN013: Recessive Dystrophic and Junctional Epidermolysis Bullosa | |
| XYZ | |
| XYZ | |
| XYZ |
Competitor Comparison
| Key Parameters | Eloxx Pharmaceuticals Inc | Vertex Pharmaceuticals Inc | PTC Therapeutics Inc | Arcturus Therapeutics Holdings Inc | Chiesi USA Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Arlington | Boston | Warren | San Diego | Cary |
| State/Province | Massachusetts | Massachusetts | New Jersey | California | North Carolina |
| No. of Employees | 10 | 6,400 | 991 | 106 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Alan Walts | Chairman | Executive Board | 2023 | 66 |
| Sumit Aggarwal | President; Director; Chief Executive Officer | Executive Board | 2021 | 54 |
| Daniel Geffken | Interim Chief Financial Officer | Senior Management | 2021 | 69 |
| Steven D. Rubin | Director | Non Executive Board | 2017 | 65 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer